CoChat
Sign Up
Cited by 111Advanced Glycation End Products researchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains

Kuhla, Björn, Boeck, Katharina, Schmidt, Angela, Ogunlade, Vera, Arendt, Thomas, Münch, Gerald, Lüth, Hans-Joachim·2007·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2005.11.007
Open this paper in CoChat — free account

Abstract

The reaction of lysine and arginine residues of proteins with 1,2-dicarbonyl compounds result in the formation of advanced glycation end products (AGEs). Accumulation of AGEs is a characteristic feature of the aging brain and contributes to the development of neurodegenerative diseases such as Alzheimer's disease (AD). Therefore, it is of particular interest to study the cellular defense mechanisms against AGE formation and particularly the detoxification of their precursors. AGE precursor compounds such as methylglyoxal and glyoxal were cellulary detoxified by the glyoxalase system, consisting of glyoxalases I and II. Glyoxalase I levels are diminished in old aged brains but elevated in AD brains. However, it is still unknown how glyoxalase I level of AD brains changes in a disease and in an age-dependent manner. Therefore, we investigated the AD stage- and the age-dependent levels of glyoxalase I in the Brodmann area 22 of AD brains (n=25) and healthy controls (n=10). Our results obtained from RT-PCR reveal reducing glyoxalase I RNA levels with advancing stage of AD and with increasing age. Western Blot analysis indicates that in comparison to healthy controls, glyoxalase I protein amounts are 1.5-fold increased in early AD subjects and continuously decrease in middle and late stages of AD. The glyoxalase I protein amounts of AD patients also decrease with age. Results obtained from glyoxalase I activity measurement show 1.05-1.2-fold diminished levels in AD brains compared to healthy controls and no significant decrease neither with the stage of AD nor with age. The immunohistochemical investigations demonstrate an elevated number of glyoxalase I stained neurons in brains of early and middle but not in late AD subjects compared to age-matched healthy controls. In addition, the stage-dependent immunohistochemical investigation demonstrates that with reduced glyoxalase I staining AGE deposits prevail, specifically in late stage of AD. In conclusion, the decrease of glyoxalase I expression with increasing AD stage might be one reason for methylglyoxal-induced neuronal impairment, apoptosis, and AGE formation in plaques and tangles.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2005.11.007

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Kuhla, B., Boeck, K., Schmidt, A., Ogunlade, V., Arendt, T., Münch, G., & Lüth, H.-J.
Affiliations
  • Leipzig University (DE)
  • James Cook University (AU)
ORCID
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2007-01
Volume
28
Issue
1
Pages
29-41
ISSN
0197-4580 (ISSN-L)
DOI
10.1016/j.neurobiolaging.2005.11.007
OpenAlex
W2045689259
Cited by
108
References
37
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 9 · 2020: 4 · 2019: 10 · 2018: 6 · 2017: 6 · 2016: 4 · 2015: 8 · 2014: 6 · 2013: 3 · 2012: 10
FWCI
2.85
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • ResearchOnline - JCU (James Cook University) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
glyoxalase I, Alzheimer's disease, advanced glycation end products, methylglyoxal, glyoxal, brain aging, disease stage, neuronal injury, apoptosis, amyloid plaques, neurodegeneration
MeSH terms
Aged, Aging, Alzheimer Disease, Brain, Enzyme Activation, Female, Humans, Lactoylglutathione Lyase, Male, Reference Values, Gene Expression, Disease Progression, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review